| News
Roivant developing treatment for coronavirus patients
23.03.2020
The Basel-based pharmaceutical company Roivant Sciences wants to develop a special antibody for coronavirus patients. This is intended to help treat and prevent acute respiratory distress syndrome.

Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant Sciences
Roivant Sciences is working on the development of a monoclonal antibody by the name of gimsilumab, as detailed in a press release. This targets the cytokine GM-CSF. According to the company, new clinical evidence is revealing that there is a connection between GM-CSF and acute respiratory distress syndrome (ARDS) in coronavirus patients. ARDS is a serious complication related to coronavirus that can see patients hospitalized or necessitate the use of mechanical ventilation or other life-support measures.
Roivant Sciences has previously tested gimsilumab in non-clinical investigations as part of a Phase 1 study. Treatment with the antibody has so far “been associated with a favorable safety and tolerability profile”, the press release states. The company has now contacted the regulatory authorities in the USA, Europe and Asia, with the aim of driving forward the clinical development of this antibody.
“Targeting GM-CSF represents a promising strategy for curbing lung damage while allowing time for the virus to clear”, comments Elizabeth Volkmann from the US institute UCLA Health, in the press release. “It is my hope that gimsilumab will reduce mortality from COVID-19 and help improve the lives of those affected by this emerging public health crisis”, she explains further.
Roivant Sciences and its subsidiaries received support from BaselArea.swiss during their efforts to establish a presence in Basel.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
VectivBio sold for approximately 1 billion dollars
The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...
Read MoreUniversity of Basel and RocketVax present new Covid vaccine
Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...
Read MoreRami Swiss and Elbit Systems now manufacturing in Jura
The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...
Read MoreBasel to become Europe’s Silicon Valley of biotech
Silicon Valley is synonymous with technology and innovation, and home to dozens of Fortune 1000 companies and thousands of startups....
Read MoreRoche and Novartis among global leaders for research spending
In 2022, Roche invested 16 billion euros in research and development overall. This puts the Basel-based life sciences firm in...
Read MoreRoche to found Institute for Human Biology
Roche has announced that it will be establishing the Institute of Human Biology in Basel. Up to 250 employees will...
Read MoreProvectis establishes presence in Basel
Provectis Healthcare has chosen Basel as the location for its headquarters. The company is striving to become the partner of...
Read MoreAlentis raises 105 million US dollars
Alentis Therapeutics has received 105 million US dollars in a series C funding round. It will invest the funds in...
Read MoreSpirecut establishes presence in the Basel Area
Spirecut has opted to establish its new headquarters in the canton of Basel-Landschaft. The company is now operating out of...
Read MoreEvolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...
Read More